New drug aims to stop bleeding in emergency surgeries for blood thinner users

NCT ID NCT07288489

Not yet recruiting Disease control Sponsor: VarmX B.V. Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 27 times

Summary

This phase 3 trial tests whether a single dose of VMX-C001 can control bleeding better than usual care in 800 patients who take blood thinners (FXa DOACs) and need urgent high-risk surgery. Participants receive either VMX-C001 or standard treatment before their procedure. The main goal is to see if bleeding control is rated good or excellent by experts who don't know which treatment was given.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Health, Melbourne

Melbourne, Victoria, 3004, Australia
Aotearoa Clinical Trials - Middlemore (ACTT) Middlemore Hospital

Papatoetoe, Auckland, 2025, New Zealand
Auckland City Hospital

Grafton, Auckand, 1023, New Zealand
Beaumont Hospital, Royal Oak

Royal Oak, Michigan, 48073, United States
Chandler Regional Medical Center (CRMC)

Chandler, Arizona, 85224, United States
Christiana Care

Newark, Delaware, 19718, United States
Denver Metro Orthopedics, P.C. - Englewood Location

Englewood, Colorado, 80113, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Fiona Stanley Hospital

Murdoch, Western Australia, 6150, Australia
Gold Coast University Hospital

Southport, Queensland, 4215, Australia
HonorHealth John C Lincoln Medical Center

Phoenix, Arizona, 85020, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mater Private Hospital

South Brisbane, Queensland, 4101, Australia
Medical Center of the Rockies

Fort Collins, Colorado, 80523, United States
Royal Brisbane and Women's Hospital (RBWH)

Herston, Queensland, 4006, Australia
St Vincent Hospital, Melbourne

Fitzroy, Victoria, 3065, Australia
St. Joseph's Hospital and Medical Center

Phoenix, Arizona, 85013, United States
Stanford Hospital and Clinics

Stanford, California, 94305, United States
Texas Tech University Health Sciences Center - El Paso

El Paso, Texas, 79905, United States
The University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73126, United States
The University of Texas McGovern Medical School at Houston

Houston, Texas, 77030, United States
University of Iowa Health Care

Iowa City, Iowa, 52242, United States
University of South Florida

Tampa, Florida, 33606, United States
Waikato Hospital

Hamilton, Waikato Region, 3204, New Zealand
Wellington Hospital

Newtown, Wellington Region, 6021, New Zealand
William Beaumont Hospital - Troy Campus

Troy, Michigan, 48085, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VMX-C001

What this could lead to

If it works, this could provide a fast, reliable way to reverse blood thinners during emergency surgeries, reducing bleeding risks.

What could go wrong

This is a phase 3 trial, but results may not apply to all patients or procedures. There is always a risk that VMX-C001 may not work better than current treatments.

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLOOD LOSS, SURGICAL COAGULATION DISORDER COAGULATION DISORDER